Ovid MEDLINE(R) 1946 to July Week 4 2014
# Searches Results Search
Type
1
Crohn Disease/ or "inflammatory bowel disease".mp. or exp inflammatory bowel diseases/ or IBD.mp. or colitis.mp. or ileitis.mp. or "ulcerative colitis".mp. or colitis, ulcerative/ or "regional enteritis".mp. or crohn*.mp. or ileocolitis.mp. or
"regional ileitis".mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
88682 Advanced
2
("tumor necrosis factor-alpha" or "tumour necrosis factor" or "anti-tnf" or "anti- tumor necrosis" or "tumor necrosis factor inhibitor" or infliximab or "monoclonal antibody*" or cA2 or remicade or adalimumab or humira or certolizumab or "CDP- 870" or CDP870 or natalizumab or antegren or tysabri or "TNF alpha antibody" or vedolizumab or MLN00002 or integrin or tofacitinib or "janus kinase").mp.
[mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease
supplementary concept, unique identifier]
382870 Advanced
3 1 and 2 7874 Advanced
4 tumor necrosis factor-alpha/ai or integrins/ai or antibodies, monoclonal/ 192609 Advanced
5 1 and 4 4853 Advanced
6 3 or 5 8407 Advanced
7 ..l/ 6 yr=1992-2014 and hu=y 6907 Advanced
8 limit 7 to (comparative study or meta analysis or randomized controlled trial or
systematic reviews) 889 Advanced
9 ("inflammatory bowel disease" or IBD or colitis or "ileitis ulcerative colitis" or
"regional enteritis" or ileocolitis or "regional ileitis").ti,ab. 57789 Advanced
10 exp *inflammatory bowel diseases/ or 9 75521 Advanced
11 7 and 10 6036 Advanced
12
11 and (random* or blinded or "double-blind").mp. [mp=title, abstract, original title, name of substance word, subject heading word, keyword heading word, protocol supplementary concept, rare disease supplementary concept, unique identifier]
643 Advanced
13 8 or 12 1174 Advanced
14
limit 13 to ("adolescent (13 to 18 years)" or "young adult (19 to 24 years)" or "adult (19 to 44 years)" or "young adult and adult (19-24 and 19-44)" or "middle age (45 to 64 years)" or "middle aged (45 plus years)" or "all aged (65 and over)" or "aged (80 and over)")
630 Advanced
15 remove duplicates from 14 503 Advanced
16 15 not animals/ 484
Cochrane CENTRAL same strategy = 184
Embase 1988 to 2014 Week 24
# Searches Results Search
Type
1
Crohn Disease/ or "inflammatory bowel disease".mp. or exp inflammatory bowel diseases/ or IBD.mp. or colitis.mp. or ileitis.mp. or "ulcerative colitis".mp. or colitis, ulcerative/ or "regional enteritis".mp. or crohn*.mp. or ileocolitis.mp. or
"regional ileitis".mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
161395 Advanced
2
("tumor necrosis factor-alpha" or "tumour necrosis factor" or "anti-tnf" or "anti- tumor necrosis" or "tumor necrosis factor inhibitor" or infliximab or "monoclonal antibody*" or cA2 or remicade or adalimumab or humira or certolizumab or "CDP- 870" or CDP870 or natalizumab or antegren or tysabri or "TNF alpha antibody" or vedolizumab or MLN00002 or integrin or tofacitinib or "janus kinase").mp.
[mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer, device trade name, keyword]
606150 Advanced
3 1 and 2 21623 Advanced
4 tumor necrosis factor-alpha/ai or integrins/ai or antibodies, monoclonal/ 147797 Advanced
5 1 and 4 3227 Advanced
6 3 or 5 21623 Advanced
7 ("inflammatory bowel disease" or IBD or colitis or "ileitis ulcerative colitis" or
"regional enteritis" or ileocolitis or "regional ileitis").ti,ab. 68474 Advanced
8 exp *inflammatory bowel diseases/ or 7 111940 Advanced
9 6 and 8 15883 Advanced
10 randomized controlled trial/ 339312 Advanced
11 9 and 10 420 Advanced
12 limit 11 to (adolescent <13 to 17 years> or adult <18 to 64 years> or aged <65+
years>) 197 Advanced
13 6 and 10 587 Advanced
14 limit 13 to (adolescent <13 to 17 years> or adult <18 to 64 years> or aged <65+
years>) 287 Advanced
15 13 and (systematic review/ or meta-analysis/) 48 Advanced
16 14 or 15 328
Web of Science
Title=(crohn* OR "ulcerative colitis" OR "inflammatory bowel" OR ibd OR colitis OR ileitis OR "regional enteritis") AND Topic=("tumor necrosis factor" OR "tumour necrosis factor"
OR "anti-tnf" OR "monoclonal antibod*" OR infliximab OR cA2 OR remicade OR
adalimumab OR humira OR certolizumab OR "CDP-870" OR CDP870 OR natalizumab OR antegren OR tysabri OR "TNF alpha antibody" OR vedolizumab OR MLN00002 OR integrin OR tofacitinib OR "janus kinase") AND Topic=((rct OR randomized OR
randomised OR placebo OR arm) AND trial*) NOT Topic=(observational OR cohort*) 859
Scopus
(TITLE((crohn* OR "ulcerative colitis" OR "inflammatory
bowel" OR ibd OR colitis OR ileitis OR ileocolitis OR "regional enteritis")) AND TITLE-ABS-KEY("tumor necrosis factor" OR "tumour necrosis factor" OR "anti-tnf" OR "monoclonal
antibod*" OR infliximab OR ca2 OR remicade OR adalimumab OR humira OR certolizumab OR "CDP- 870" OR cdp870OR natalizumab OR antegren OR tysabri OR "TNF alpha antibody") OR TITLE-ABS- KEY(vedolizumab OR mln00002 ORintegrin OR tofacitinib OR "janus kinase") AND TITLE-ABS- KEY((randomized OR randomised OR "double blind" ORplacebo* OR arm) AND trial*)) AND PUBYEAR
> 1991 AND NOT (PMID(1* OR 2* OR 3* OR 4* OR 5* OR 6* OR 7* OR8* OR 9*)) 369
